Tagrisso treats non-small cell lung cancer (NSCLC). It is specifically for those who have the EGFR T790M mutation.
Tagrisso is a prescription medication used to treat non-small cell lung cancer. Tagrisso is specifically for those patients who have metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
It belongs to a group of drugs called protein kinase inhibitors. These drugs help by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
This medication is available in tablet form. It is typically taken once a day, with or without food.
Common side effects include diarrhea as well as skin and nail conditions.
Patient Ratings for
How was your experience with ?
Uses of Tagrisso
- has a certain type of abnormal epidermal growth factor receptor (EGFR) gene, and
- you have had previous treatment with an EGFR tyrosine kinase inhibitor medicine and it has stopped working.
Your doctor will perform a test to make sure that Tagrisso is right for you.
It is not known if Tagrisso is safe and effective in children.
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Tagrisso Drug Class
Tagrisso is part of the drug class:
Side Effects of Tagrisso
Serious side effects have been reported with Tagrisso. See the “Tagrisso Precautions” section.
Common side effects of Tagrisso include the following:
- dry skin
- changes in the nails (redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails)
This is not a complete list of Tagrisso side effects. Ask your doctor or pharmacist for more information.
Tell your doctor if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take:
- medications that block a protein in the body (CYP3A4) such as some macrolide antibiotics (clarithromycin, telithromycin), some HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (boceprevir, telaprevir), some azole antifungals (ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan (Vaprisol), delavirdine (Rescriptor), and nefazodone. When taken together with Tagrisso, these medications can increase the levels of Tagrisso and cause more side effects or toxicity.
- medications that increase the activity of the enzyme CYP3A4 such as carbamazepine (Tegretol, Equetro, Carbatrol), phenobarbital, phenytoin (Dilantin), rifampin (Rifadin), St John's wort, and nimodipine (Nimotop). When taken together with Tagrisso, these medications can decrease Tagrisso levels in the body.
This is not a complete list of Tagrisso drug interactions. Ask your doctor or pharmacist for more information.
Serious side effects have been reported with Tagrisso including the following:
- lung problems. Tagrisso may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.
- heart problems, including heart failure. Tagrisso may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking Tagrisso and during treatment. Call your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.
- harm to your unborn baby. Tagrisso may cause fetal harm. Women are recommended to use effective contraception during treatment and for 6 weeks after final dose. Males who have female partners that are able to become pregnant should use effective birth control during treatment with Tagrisso and for 4 months after the final dose of Tagrisso.
Do not take Tagrisso if you are allergic to Tagrisso or any of its ingredients.
Tagrisso Food Interactions
Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Tagrisso, there are no specific foods that you must exclude from your diet when receiving this medication.
Before taking Tagrisso, tell your doctor about all of your medical conditions. Especially tell your doctor if you:
- are allergic to Tagrisso or to any of its ingredients
- have lung or breathing problems
- have heart problems, including a condition called long QTc syndrome
- have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
- are pregnant or plan to become pregnant. Tagrisso can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with Tagrisso or think you may be pregnant.
- Females who are able to become pregnant should use an effective birth control during treatment with Tagrisso and for 6 weeks after the final dose of Tagrisso.
- Males who have female partners that are able to become pregnant should use effective birth control during treatment with Tagrisso and for 4 months after the final dose of Tagrisso.
- are breastfeeding or plan to breastfeed. It is not known if Tagrisso passes into your breast milk. Do not breastfeed during treatment with Tagrisso and for 2 weeks after your final dose of Tagrisso. Talk to your doctor about the best way to feed your baby during this time.
Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.
Tagrisso and Pregnancy
Tell your doctor if you are pregnant or plan to become pregnant.
Based on data from animal studies and its mechanism of action, Tagrisso can cause fetal harm when administered to a pregnant woman. There are no available data on Tagrisso use in pregnant women.
Tagrisso and Lactation
Tell your doctor if you are breastfeeding or plan to breastfeed.
It is not known if Tagrisso crosses into human milk. Asmistartaion to rats during early lactation was associated with adverse events.
Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication, lactating women should NOT breastfeed during treatment with Tagrisso and for 2 weeks after final dose.
Take Tagrisso exactly as your doctor tells you to take it.
Your doctor may change your dose, temporarily stop, or permanently stop treatment with Tagrisso if you have side effects.
Tagrisso is available in tablet form. It is typically taken once a day, with or without food.
If you miss a dose of Tagrisso, do not make up for the missed dose. Take your next dose at your regular time.
If you cannot swallow Tagrisso tablets whole:
- place your dose of Tagrisso in a container that contains 2 ounces of water. Do not use carbonated water or any other liquids.
- stir the Tagrisso tablet and water until the Tagrisso tablet is in small pieces (the tablet will not completely dissolve). Do not crush or heat.
- drink the Tagrisso and water mixture right away.
- add 4 to 8 ounces of water into the container and drink to make sure that you take your full dose of Tagrisso.
Take this medication exactly as prescribed by your doctor. Follow the directions on your prescription label carefully.
If you take too much Tagrisso, call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.
- Store Tagrisso at room temperature between 68°F to 77°F (20°C to 25°C).
- Safely throw away medicine that is out of date or that you no longer need.
- Keep Tagrisso and all medicines out of the reach of children.